> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ADC Therapeutics Sees $21 Million In ZYNLONTA Sales And Cash Lasting Into 2029
- URL: https://www.bullished.co/adc-therapeutics-sees-21-million-in-zynlonta-sales-and-cash-lasting-into-2029-8e18cb78/
- Published: 2026-11-04T21:07:32.000Z
- Updated: 2026-11-04T21:07:32.000Z
- Description: The lymphoma drugmaker also reported an 88.7% response rate for ZYNLONTA plus glofitamab and previewed five oral talks at December's ASH meeting.
- Author: Matteo Parrino
- Tags: SEC Filings, ADCT, Industry: Healthcare

[ADC Therapeutics](https://www.bullished.co/tag/adct/), which develops cancer drugs that pair a tumor-targeting antibody with a toxin, expects [$21 million](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9902.htm?ref=bullished.co) in third-quarter net sales of its lymphoma drug ZYNLONTA and says its cash should last into 2029 after a restructuring of its financing. The company laid out the preliminary figures in an [8-K filed Wednesday](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5F8k.htm?ref=bullished.co), alongside new trial data headed for the American Society of Hematology meeting.

## Sales up, cash down, runway extended

The $21 million estimate for the quarter ended September 30 compares with $16 million a year earlier. For the first nine months, expected sales are $60 million against $51 million. The company attributed the gains primarily to higher sales volume. The figures are preliminary and not yet finalized by management.

Cash and equivalents were $189.2 million at September 30, down from $219 million at the end of the second quarter. The third-quarter spending included $13 million of one-time severance and retention payments. Pro forma cash after the financing steps is $196 million.

That adjusted figure counts about $76 million of net proceeds from the private placement and a $68.5 million partial prepayment of the senior secured term loan, which closed on October 22.

## A $86.6 million raise and a loan reset

The restructuring has several separate pieces. The company announced an $86.6 million private placement with Bain Capital Life Sciences as a new investor and Redmile, TCGX and Nantahala Capital among existing ones.

It amended its HealthCare Royalty financing agreement, removing a $150 million change-of-control payment, and cut the exercise price on about 9.8 million warrants from $3.8130 to $0.10.

Separately, the senior secured loan was refinanced to $50 million of principal, due as a single payment in August 2029, with no minimum liquidity requirement. Its revenue covenant is a flat $65 million, versus $70 million in 2026 and up to $94 million in 2029.

## Lymphoma data for ASH

The company will present five oral talks at the meeting in New Orleans, December 12 to 15\. In the early-stage LOTIS-7 trial of ZYNLONTA plus glofitamab, [97 evaluable patients](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9901.htm?ref=bullished.co) showed an 88.7% overall response rate and a 75.3% complete response rate as of a June 15 data cutoff. Cytokine release syndrome occurred in 32% of patients, and three deaths were treatment-related adverse events.

A investigator-led marginal zone lymphoma study of 43 evaluable patients showed a 93% response rate and [74.4% complete responses](https://www.prnewswire.com/news-releases/adc-therapeutics-announces-abstracts-at-the-68th-ash-annual-meeting-highlighting-breadth-of-zynlonta-clinical-program-302928676.html?ref=bullished.co).

The full Phase 3 LOTIS-5 results will also be presented. The trial met its main goal of progression-free survival, 6.14 months versus 4.73 months for chemotherapy, but deaths from adverse events were higher in the ZYNLONTA arm, 13.2% versus 4.6% within the protocol window. The company's forward-looking statements cite serious concerns the FDA raised at a recent pre-submission meeting, and it expects to update its regulatory strategy later.

CEO Ameet Mallik said the LOTIS-7 and marginal zone data support "an expanded role in treating these B-cell malignancies through potential compendia and regulatory pathways."

ADC Therapeutics reports full third-quarter results on Monday, November 9.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ADC Therapeutics SA (ADCT)](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit dp256258\_ex9901.htm — ADC Therapeutics SA 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9901.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit dp256258\_ex9902.htm — ADC Therapeutics SA 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001771910/000095010326016945/dp256258%5Fex9902.htm?ref=bullished.co) — SEC EDGAR
- [ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611020715PR%5FNEWS%5FUSPRX%5F%5F%5F%5FNY85986-1&ref=bullished.co) — Financial Times
- [ADC Therapeutics Announces ZYNLONTA® Updates in Japan](https://finance.yahoo.com/healthcare/articles/adc-therapeutics-announces-zynlonta-updates-113000613.html?ref=bullished.co) — Yahoo Finance
- [ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program](https://www.prnewswire.com/news-releases/adc-therapeutics-announces-abstracts-at-the-68th-ash-annual-meeting-highlighting-breadth-of-zynlonta-clinical-program-302928676.html?ref=bullished.co) — prnewswire.com

### More on ADC Therapeutics

- [ADC Therapeutics Seeks To Leave Switzerland For Delaware, Converting Every Share One-For-One](https://www.bullished.co/adc-therapeutics-seeks-to-leave-switzerland-for-delaware-converting-every-share-one-for-9ff5ee68/)
- [Bain Capital Life Sciences Fund Reports 9.99% Passive Stake In ADC Therapeutics](https://www.bullished.co/bain-capital-life-sciences-fund-reports-9-99-passive-stake-in-adc-therapeutics-68037e23/)
- [ADC Therapeutics Plans $86.6 Million Share Sale, Cuts Loan To $50.0 Million, Drops $150 Million Change-Of-Control Payment](https://www.bullished.co/adc-therapeutics-plans-86-6-million-share-sale-cuts-loan-to-50-0-million-drops-150-million-6a85af48/)

[All ADC Therapeutics (ADCT) coverage →](https://www.bullished.co/tag/adct/)